Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Santhera Closes License-Back Deal with Takeda

Published: Friday, September 27, 2013
Last Updated: Friday, September 27, 2013
Bookmark and Share
Agreement with Takeda to license back previously granted European rights to Catena® in DMD.

Santhera Pharmaceuticals has announced that it has reached an agreement with Takeda to license back previously granted European rights to Catena® (INN: idebenone) in Duchenne Muscular Dystrophy (DMD).

In a back-loaded deal, Santhera regains European commercialization rights for Catena®. The drug is currently being investigated in a Phase III study in DMD conducted in Europe and in the USA.

In 2007, Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda") acquired the exclusive marketing rights in Europe and Switzerland for Catena® for the treatment of DMD.

Under the agreement reached, Santhera licenses back all such previously granted rights to increase its strategic flexibility. In return, Takeda is eligible to obtain a percentage from future licensing and/or sales income generated by Santhera in DMD.

In addition, Santhera has obtained the right to cross-reference Takeda's idebenone data for regulatory use in any indication in any territory.

If Santhera makes use of such cross-reference right, Takeda is eligible to obtain a percentage from future licensing and/or sales income generated by Santhera in such indications.

Lastly, both companies agreed to terminate a similar agreement for Friedreich's Ataxia signed in 2005 and Santhera's previously disclosed contingent liability of EUR 1 million payable to Takeda has been waived.

Takeda is eligible to receive Euro 1 million as a percentage from future income generated by Santhera to offset this waiver.

"The agreement we reached today with Takeda clearly increases our strategic flexibility. Potential licensees interested in Catena® in DMD can now be offered global rights to this program", commented Thomas Meier, CEO of Santhera.

Meier continued, "The ongoing DELOS study has recently passed a futility analysis and we expect to report top-line data from the first cohort of patients in this study in the second quarter of 2014. Today's agreement with Takeda also grants us right of cross-reference to certain data which may be needed for any regulatory filings for indications currently being developed or which may be developed in the future."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Tuesday, July 21, 2015
CHMP Recommends Granting a Marketing Authorization for Santhera's Raxone®
Raxone® (idebenone) for the treatment of visual impairment in adolescent and adult patients with LHON.
Friday, June 26, 2015
Santhera Update on Pre-NDA Meeting with FDA
Company plans to submit a New Drug Application for Raxone®/Catena® (idebenone) in Duchenne Muscular Dystrophy.
Tuesday, June 16, 2015
Santhera's Positive Phase III Trial in DMD Patients Published in The Lancet
First successful Phase III trial in DMD shows Raxone®/Catena® preserves respiratory function.
Thursday, April 23, 2015
Santhera Receives FDA Fast Track Designation for Raxone®/Catena®
Fast Track designation for the treatment of Duchenne Muscular Dystrophy.
Friday, April 10, 2015
Santhera Repositions Omigapil in Congenital Muscular Dystrophy
Company initiates clinical development program with public-private partners.
Thursday, July 17, 2014
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in DMD
Positive outcome indicates that Catena®/Raxone® can mitigate respiratory weakness and dysfunction.
Tuesday, May 27, 2014
Santhera Secures Exclusive Rights from NIH
Santhera has obtained the exclusive rights to the use patent for idebenone in ppMS granted in the USA.
Monday, June 10, 2013
Santhera Obtains US Patent for Use of Catena® in the Treatment of Muscular Dystrophies
The patent in the United States is supplemented by a similar patent in the European Union granted in 2010.
Wednesday, August 24, 2011
Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting
Results from the RHODOS study evaluate the efficacy of Catena® in Leber Hereditary Optic Neuropathy.
Tuesday, June 07, 2011
Fipamezole Transition from Biovail Completed - Program Well Advanced Towards Phase III
Fipamezole is being developed as a potential first treatment of Dyskinesia in Parkinson's Disease.
Wednesday, February 23, 2011
Santhera Licenses Melanocortin-4 Receptor Antagonist Program to BioLineRx
BioLineRx acquires all rights to develop, sub-license and commercialize the compound.
Thursday, October 14, 2010
Santhera and Ipsen Enter into Licensing Agreement for Fipame-zole for the Treatment of Dyskinesia in Parkinson's Disease
Ipsen acquires the rights to fipamezole outside the United States, Canada and Japan for an upfront payment of EUR 13 million.
Friday, September 03, 2010
Santhera Obtains European Patent for Use of Catena®/Sovrima®
Patent covers the treatment or prevention of weakness and loss of skeletal muscle tissue including Duchenne Muscular Dystrophy and other muscular dystrophies.
Wednesday, August 18, 2010
Santhera Presents New Data on MC-4R Antagonist Program for Treatment of Cancer Cachexia
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, recently presented the potential of its oral melanocortin-4 receptor (MC-4R) antagonists for treatment of cancer cachexia at the 5th Cachexia conference in Barcelona, Spain.
Tuesday, December 08, 2009
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!